molmed

Investors

Publication of the Interim financial report as of September 30th 2019

Publication of the Interim financial report as of September 30th 2019 ▾

Investors

Interim financial report as of September 30 2019

Interim financial report as of September 30 2019 ▾

Investors

Board of Directors approves financial results for the nine months ended September 30 2019

Board of Directors approves financial results for the nine months ended September 30 2019 ▾

News & Events

Stay update

European Society of Gene & Cell Therapy (ESGCT) Barcelona, Spain ▾

European Society of Gene & Cell Therapy (ESGCT) Barcelona, Spain

Investors

MolMed informs on its decision to withdraw the Conditional Marketing Authorization of Zalmoxis

MolMed informs on its decision to withdraw the Conditional Marketing Authorization of Zalmoxis ▾

News & Events

Stay update

ARM Cell & Gene Meeting on the MESA 2019 ▾

ARM Cell & Gene Meeting on the MESA 2019

Location:

Carlsbad, California (USA), Cognate Bioservices Ballroom Wednesday October 3:15pm

MolMed at this event:

Company presentation

Investors

Lombardy Region approved the "agreement for innovation" scheme for the financing, together with the Ministry of Economic Development, of MolMed’s project proposal "New CAR therapies for the treatment of cancer patients"

Lombardy Region approved the "agreement for innovation" scheme for the financing, together with the Ministry of Economic Development, of MolMed’s project proposal "New CAR therapies for the treatment of cancer patients" ▾

Governance

Report on corporate governance and ownership structure 2015 (in Italian) ▾

Report on corporate governance and ownership structure 2015 (in Italian)

Governance

Annual remuneration report 2015 (in Italian) ▾

Annual remuneration report 2015 (in Italian)

Governance

Annual remuneration report 2016 (in Italian) ▾

Annual remuneration report 2016 (in Italian)

Subscribe to

Subscribe to press releases

Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.